Alectinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ALECTINIB |
|---|---|
| Type | Drug |
| Aliases | AlecensaАлектиніб |
| Status | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | 2nd-generation ALK inhibitor (CNS-penetrant) |
|---|---|
| Mechanism | ALK + RET inhibitor with excellent CNS penetration. ALEX: superior PFS + intracranial response vs crizotinib in 1L ALK-rearranged metastatic. Adjuvant ALINA: 3-year DFS benefit in resected ALK+ stage IB-IIIA. |
| Typical dosing | 600 mg PO BID with food. Adjuvant ALINA: 600 mg BID x 2 years. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Workhorse 1L ALK inhibitor. CNS efficacy critical (high CNS-met rate in ALK+).
Used By
Regimens
REG-ALECTINIB-NSCLC- Alectinib monotherapy (ALK+ NSCLC, 1L metastatic OR adjuvant)